Literature DB >> 25256353

Activation of AMP-activated protein kinase α1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis.

Yu-Ju Liu1, Tz-Chuen Ju2, Hui-Mei Chen2, Yu-Sung Jang2, Li-Ming Lee3, Hsing-Lin Lai2, Hua-Chia Tai4, Jim-Min Fang4, Yun-Lian Lin5, Pang-Hsien Tu6, Yijuang Chern7.   

Abstract

TAR DNA-binding protein-43 (TDP-43) is a nuclear RNA-binding protein involved in many cellular pathways. TDP-43-positive inclusions are a hallmark of amyotrophic lateral sclerosis (ALS). The major clinical presentation of ALS is muscle weakness due to the degeneration of motor neurons. Mislocalization of TDP-43 from the nucleus to the cytoplasm is an early event of ALS. In this study, we demonstrate that cytoplasmic mislocalization of TDP-43 was accompanied by increased activation of AMP-activated protein kinase (AMPK) in motor neurons of ALS patients. The activation of AMPK in a motor neuron cell line (NSC34) or mouse spinal cords induced the mislocalization of TDP-43, recapitulating this characteristic of ALS. Down-regulation of AMPK-α1 or exogenous expression of a dominant-negative AMPK-α1 mutant reduced TDP-43 mislocalization. Suppression of AMPK activity using cAMP-simulating agents rescued the mislocalization of TDP-43 in NSC34 cells and delayed disease progression in TDP-43 transgenic mice. Our findings demonstrate that activation of AMPK-α1 plays a critical role in TDP-43 mislocalization and the development of ALS; thus, AMPK-α1 may be a potential drug target for this devastating disease.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25256353     DOI: 10.1093/hmg/ddu497

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  25 in total

1.  Early ALS-type gait abnormalities in AMP-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease.

Authors:  Maxime Vergouts; Claudia Marinangeli; Caroline Ingelbrecht; Geraldine Genard; Olivier Schakman; Anthony Sternotte; André-Guilhem Calas; Emmanuel Hermans
Journal:  Metab Brain Dis       Date:  2015-07-09       Impact factor: 3.584

Review 2.  AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis.

Authors:  Nirma D Perera; Bradley J Turner
Journal:  Neurochem Res       Date:  2015-07-23       Impact factor: 3.996

Review 3.  Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis.

Authors:  Andrew T Nelson; Davide Trotti
Journal:  Neurotherapeutics       Date:  2022-06-30       Impact factor: 6.088

Review 4.  Demethyleneberberine, a potential therapeutic agent in neurodegenerative disorders: a proposed mechanistic insight.

Authors:  Priyanka Saklani; Heena Khan; Thakur Gurjeet Singh; Saurabh Gupta; Amarjot Kaur Grewal
Journal:  Mol Biol Rep       Date:  2022-06-03       Impact factor: 2.742

5.  Imaging Neurodegenerative Metabolism in Amyotrophic Lateral Sclerosis with Hyperpolarized [1-13C]pyruvate MRI.

Authors:  Nikolaj Bøgh; Christoffer Laustsen; Esben S S Hansen; Hatice Tankisi; Lotte B Bertelsen; Jakob U Blicher
Journal:  Tomography       Date:  2022-06-14

Review 6.  Neuroimmunometabolism: A New Pathological Nexus Underlying Neurodegenerative Disorders.

Authors:  Swarup Mitra; Avijit Banik; Sumit Saurabh; Malabika Maulik; Shailesh N Khatri
Journal:  J Neurosci       Date:  2022-01-13       Impact factor: 6.709

7.  Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.

Authors:  Roberta Cascella; Claudia Capitini; Giulia Fani; Christopher M Dobson; Cristina Cecchi; Fabrizio Chiti
Journal:  J Biol Chem       Date:  2016-07-21       Impact factor: 5.157

Review 8.  Importance of lipids for upper motor neuron health and disease.

Authors:  Aksu Gunay; Heather H Shin; Oge Gozutok; Mukesh Gautam; P Hande Ozdinler
Journal:  Semin Cell Dev Biol       Date:  2020-12-13       Impact factor: 7.727

Review 9.  Cysteine Modifications in the Pathogenesis of ALS.

Authors:  Cristiana Valle; Maria Teresa Carrì
Journal:  Front Mol Neurosci       Date:  2017-01-23       Impact factor: 5.639

Review 10.  What is "Hyper" in the ALS Hypermetabolism?

Authors:  Alberto Ferri; Roberto Coccurello
Journal:  Mediators Inflamm       Date:  2017-09-07       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.